Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 201–300 of 1,007
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 188
“Angiogenesis is also required for the development of primary tumors and metastases (Algire et al. 1945; Folkman 1995; Ferrara and Kerbel 2005).”
BackgroundSelf-citationMyeloid lineage progenitors give rise to vascular endothelium
Bailey, A. S., Willenbring, H., Jiang, S., Anderson, D. A., Schroeder, D. A., Wong, M. H., Grompe, M., & Fleming, W. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604203103 · Cited by 187
Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
Girotti, M. R., Salatino, M., Dalotto-Moreno, T., & Rabinovich, G. A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20182041 · Cited by 185
“Tyrosine kinase inhibitors, as well as specific monoclonal antibodies, disrupt angiogenesis through inhibition of VEGF and their cognate receptors (Ferrara and Kerbel, 2005).”
BackgroundCabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., et al. (2015) · Cancer · doi:10.1002/cncr.29395 · Cited by 186
“Dyspnea 18 (31) 0 (0) Musculoskeletal pain 18 (31) 1 (2)”
BackgroundJi, T., Zhao, Y., Ding, Y., & Nie, G. (2013) · Advanced Materials · doi:10.1002/adma.201300299 · Cited by 183
Exercise and PGC-1α-Independent Synchronization of Type I Muscle Metabolism and Vasculature by ERRγ
Narkar, V. A., Fan, W., Downes, M., Yu, R. T., Jonker, J. W., Alaynick, W. A., Banayo, E., Karunasiri, M. S., Lorca, S., & Evans, R. M. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.019 · Cited by 183
Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
Lähteenvuo, M., Honkonen, K., Tervala, T., Tammela, T., Suominen, E., Lähteenvuo, J., Kholová, I., Alitalo, K., Ylä-Herttuala, S., & Saaristo, A. (2011) · Circulation · doi:10.1161/circulationaha.110.965384 · Cited by 184
Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors
Akino, T., Hida, K., Hida, Y., Tsuchiya, K., Freedman, D., Muraki, C., Ohga, N., Matsuda, K., Akiyama, K., Harabayashi, T., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090202 · Cited by 183
“CD133 mTECs showed aneuploidy more frequently than CD133 mTECs.”
BackgroundInfluentialEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
Walia, A., Yang, J. F., Huang, Y.-H., Rosenblatt, M. I., Chang, J.-H., & Azar, D. T. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.09.007 · Cited by 182
“37 Understandably, the next step in endostatin-related research will focus on drug delivery and determining whether combinatory therapies can be more efficacious than endostatin monotherapy [227, 228].”
Bruno, A., Ferlazzo, G., Albini, A., & Noonan, D. M. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju200 · Cited by 184
Applications of inorganic nanoparticles as therapeutic agents
Kim, T., & Hyeon, T. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/1/012001 · Cited by 180
Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
Schmid, M. C., & Varner, J. A. (2010) · Journal of Oncology · doi:10.1155/2010/201026 · Cited by 180
“Anti-angiogenic agents were already described to be the most efficacious when combined with cytotoxic agents and/or therapies targeted towards ablating myeloid cells [5, 101].”
BackgroundGunasekera, S., Foley, F. M., Clark, R. J., Sando, L., Fabri, L. J., Craik, D. J., & Daly, N. L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800704e · Cited by 180
CXCR2‐mediated tumor‐associated neutrophil recruitment is regulated by IFN‐β
Jablonska, J., Wu, C. ‐., Andzinski, L., Leschner, S., & Weiss, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.28551 · Cited by 179
Catecholamines Regulate Tumor Angiogenesis
Chakroborty, D., Sarkar, C., Basu, B., Dasgupta, P. S., & Basu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4289 · Cited by 181
Dray, C., Rougon, G., & Debarbieux, F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900222106 · Cited by 183
“This might be achieved by stabilization and consolidation of neovessels in the long term by manipulating posttraumatic angiogenesis (31).”
BackgroundNeergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L.-S., & Aruoma, O. I. (2010) · Toxicology · doi:10.1016/j.tox.2009.10.010 · Cited by 179
“Thus, suppresion of abnormal angiogenesis may provide strategies for halting he process of carcinogenesis (Ferrara and Kerbel, 2005).”
BackgroundPatel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., & Bonomi, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8181 · Cited by 178
Interaction between Bevacizumab and Murine VEGF-A: A Reassessment
Yu, L., Wu, X., Cheng, Z., Lee, C. V., LeCouter, J., Campa, C., Fuh, G., Lowman, H., & Ferrara, N. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1175 · Cited by 180
“Conversely, antiangiogenesis is a validated strategy to treat a number of disorders, including solid tumors and intraocular neovascular syndromes.(3,4) One of the key mediators of physiological and pathologic angiogenesis is vascular endothelial growth factor (VEGF)-A.”
BackgroundSelf-citationDatla, S. R., Peshavariya, H., Dusting, G. J., Mahadev, K., Goldstein, B. J., & Jiang, F. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.149450 · Cited by 178
Huang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
Funk, M., Karl, D., Georgopoulos, M., Benesch, T., Sacu, S., Polak, K., Zlabinger, G. J., & Schmidt-Erfurth, U. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.039 · Cited by 175
Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models
Sarkar, C., Chakroborty, D., Chowdhury, U. R., Dasgupta, P. S., & Basu, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1778 · Cited by 174
“In addition, although new serious toxicities are being reported with the use of presently available anti–VPF/VEGF agents (5, 7), dopamine is a wellestablished drug with known and manageable toxicity (44).”
BackgroundAntiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
de Boüard, S., Herlin, P., Christensen, J. G., Lemoisson, E., Gauduchon, P., Raymond, E., & Guillamo, J.-S. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-024 · Cited by 180
Detection and Tracking of Multiple Microbubbles in Ultrasound B-Mode Images
Ackermann, D., & Schmitz, G. (2016) · IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control · doi:10.1109/tuffc.2015.2500266 · Cited by 172
“I N CANCER research, angiogenesis is of particular interest [1], as the formation of small new vessels indicates the onset of tumor growth [2], and antiangiogenic therapy [3] is a promising approach for tumor treatment.”
BackgroundRefractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
Self-citationTherapeutic application of anti-angiogenic nanomaterials in cancers
Mukherjee, S., & Patra, C. R. (2016) · Nanoscale · doi:10.1039/c5nr07887c · Cited by 169
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169
“…modifiers of tumor vasculature In addition to therapeutic strategies designed to directly target the tumor blood vessel network,many other agents currently in use for cancer management can affect components of the angiogenesis network or inhibit angiogenesis indirectly (Ferrara & Kerbel, 2005).”
Endothelial Progenitor Cells for the Vascularization of Engineered Tissues
Peters, E. B. (2018) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2017.0127 · Cited by 171
“Additionally, inducing EPCs to form macrovasculature within the prevascularized construct could create a vascular axis within the construct, enabling microsurgical connection with the host vasculature and instantly perfusing the scaffold with blood.(223,146) Assisting efforts to advance EPC vascularization research is…”
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091846 · Cited by 170
“20091846 491 Angiogenesis is a pivotal process for growth, invasion, and spread of tumors and is therefore used as a therapeutic target in many types of cancer (Hanahan and Folkman, 1996; Ferrara and Kerbel, 2005).”
BackgroundVascular endothelial growth factor receptor 3 directly regulates murine neurogenesis
Calvo, C.-F., Fontaine, R. H., Soueid, J., Tammela, T., Makinen, T., Alfaro-Cervello, C., Bonnaud, F., Miguez, A., Benhaim, L., Xu, Y., et al. (2011) · Genes & Development · doi:10.1101/gad.615311 · Cited by 171
“In the vascular system, VEGF-A regulates angiogenesis and vascular permeability via its receptors, VEGFR-2 and VEGFR-1 (Carmeliet 2005; Ferrara and Kerbel 2005), while VEGF-C is required for lymphangiogenesis and angiogenesis via VEGFR-3, which is expressed in lymphatic endothelial cells and…”
BackgroundApelin is a potent activator of tumour neoangiogenesis
Sorli, S. C., Le Gonidec, S., Knibiehler, B., & Audigier, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210573 · Cited by 169
Lu, J., Zhang, K., Nam, S., Anderson, R. A., Jove, R., & Wen, W. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp292 · Cited by 167
Role of myeloid cells in tumor angiogenesis and growth
Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.06.003 · Cited by 167
Self-citationFonsatti, E., Nicolay, H. J. M., Altomonte, M., Covre, A., & Maio, M. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvp332 · Cited by 165
Wang, J., Liu, J., Liu, Y., Wang, L., Cao, M., Ji, Y., Wu, X., Xu, Y., Bai, B., Miao, Q., et al. (2016) · Advanced Materials · doi:10.1002/adma.201603114 · Cited by 166
Endothelial α5 and αv integrins cooperate in remodeling of the vasculature during development
van der Flier, A., Badu-Nkansah, K., Whittaker, C. A., Crowley, D., Bronson, R. T., Lacy-Hulbert, A., & Hynes, R. O. (2010) · Development · doi:10.1242/dev.049551 · Cited by 162
“INTRODUCTION Vascular and congenital heart diseases are major causes of lethality (Bruneau, 2008) and much effort has been directed towards developing anti-angiogenic drugs (Ferrara and Kerbel, 2005).”
BackgroundDecorin Antagonizes the Angiogenic Network
Neill, T., Painter, H., Buraschi, S., Owens, R. T., Lisanti, M. P., Schaefer, L., & Iozzo, R. V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.283499 · Cited by 165
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.200918462104c · Cited by 163
Boronate affinity monolith for highly selective enrichment of glycopeptides and glycoproteins
Chen, M., Lu, Y., Ma, Q., Guo, L., & Feng, Y.-Q. (2009) · The Analyst · doi:10.1039/b909581k · Cited by 161
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 202
Encyclopedia of Nanotechnology
(2016) · Springer eBooks · doi:10.1007/978-94-017-9780-1 · Cited by 160
VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis
Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A. C., & Mignatti, P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605556103 · Cited by 160
Song, M., Yeku, O. O., Rafiq, S., Purdon, T., Dong, X., Zhu, L., Zhang, T., Wang, H., Yu, Z., Mai, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20140-0 · Cited by 158
Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets
Alghisi, G. C., & Rüegg, C. (2006) · Endothelium · doi:10.1080/10623320600698037 · Cited by 159
Investigation of Vaporized Submicron Perfluorocarbon Droplets as an Ultrasound Contrast Agent
Reznik, N., Williams, R., & Burns, P. N. (2011) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2011.05.001 · Cited by 160
Differential roles of PDGFR‐α and PDGFR‐β in angiogenesis and vessel stability
Zhang, J., Cao, R., Zhang, Y., Jia, T., Cao, Y., & Wahlberg, E. (2009) · The FASEB Journal · doi:10.1096/fj.08-113860 · Cited by 162
KATOH, M. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1444 · Cited by 156
“Angiogenesis is a process of neovascular formation from pre-existing blood vessels during embryogenesis, adult tissue homeostasis and carcinogenesis (1-4).”
BackgroundLysyl Oxidase Plays a Critical Role in Endothelial Cell Stimulation to Drive Tumor Angiogenesis
Baker, A.-M., Bird, D., Welti, J. C., Gourlaouen, M., Lang, G., Murray, G. I., Reynolds, A. R., Cox, T. R., & Erler, J. T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2447 · Cited by 157
“Formation of new blood vessels, a process known as angiogenesis, is essential for tumor growth and progression (12, 13).”
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 164
Li, B., Chu, T., Wei, J., Zhang, Y., Qi, F., Lu, Z., Gao, C., Zhang, T., Jiang, E., Xu, J., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00168 · Cited by 157
Klein, D., Weißhardt, P., Kleff, V., Jastrow, H., Jakob, H. G., & Ergün, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020540 · Cited by 170
Bagri, A., Tessier-Lavigne, M., & Watts, R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0563 · Cited by 154
Siveen, K. S., Ahn, K. S., Ong, T. H., Shanmugam, M. K., Li, F., Yap, W. N., Kumar, A. P., Fong, C. W., Tergaonkar, V., Hui, K. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1876 · Cited by 152
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth
Cho, W. G., Albuquerque, R. J. C., Kleinman, M. E., Tarallo, V., Greco, A., Nozaki, M., Green, M. G., Baffi, J. Z., Ambati, B. K., De Falco, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812317106 · Cited by 149
“Pathological responses of these parallel circulatory systems can lead to diseases as varied as age-related macular degeneration, atherosclerosis, cancer, lymphedema, and rheumatoid arthritis (1).”
BackgroundKoh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 166
“Of these factors, VEGF-A is a prime molecule responsible for tumor progression and metastasis by enhancing angiogenesis and vascular leakage (Ferrara and Kerbel, 2005; Folkman, 2007).”
VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)
Peng, F.-W., Liu, D., Zhang, Q., Xu, Y., & Shi, L. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344215 · Cited by 160
Wang, X., Li, J., Bian, X., Wu, C., Hua, J., Chang, S., Yu, T., Li, H., Li, Y., Hu, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012881118 · Cited by 187
Sessa, C., Guibal, A., Conte, G. D., & Rüegg, C. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1150 · Cited by 157
“dtd" [ ]> Introduction Tumor angiogenesis is a tumor microenvironmental process that promotes tumor-cell survival, growth, invasion and metastasis, and its inhibition is emerging as a new therapeutic approach to control tumor progression”
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
Tentori, L., Lacal, P. M., Muzi, A., Dorio, A. S., Leonetti, C., Scarsella, M., Ruffini, F., Xu, W., Min, W., Stoppacciaro, A., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.010 · Cited by 159
Multifunctional Nanoparticulate Polyelectrolyte Complexes
Hartig, S. M., Greene, R. R., Dikov, M. M., Prokop, A., & Davidson, J. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9459-1 · Cited by 167
“Extensive research has led to the identification and isolation of several regulators of angiogenesis, some of which represent therapeutic targets (125,126).”
BackgroundAntiangiogenic Activity of Brown Algae Fucoxanthin and Its Deacetylated Product, Fucoxanthinol
Sugawara, T., Matsubara, K., Akagi, R., Mori, M., & Hirata, T. (2006) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf062204q · Cited by 148
Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B
Lejmi, E., Leconte, L., Pédron-Mazoyer, S., Ropert, S., Raoul, W., Lavalette, S., Bouras, I., Feron, J.-G., Maitre-Boube, M., Assayag, F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804008105 · Cited by 149
Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer
McKeage, M. J., & Baguley, B. C. (2010) · Cancer · doi:10.1002/cncr.24975 · Cited by 148
“growth and limiting metastatic potential, and have been reviewed elsewhere.(35,36) The differences between antiangiogenic agents and tumor-VDAs may result in distinct toxicity profiles, offering potential for their use in combi-”
BackgroundFu, W.-M., Lu, Y., Hu, B., Liang, W., Zhu, X. M., Yang, H.-D., Li, G., & Zhang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6731 · Cited by 152
“On the other hand, anti-angiogenic agents impair the growth of tumor because of inadequate blood supply [19–20].”
Chakroborty, D., Chowdhury, U. R., Sarkar, C., Baral, R., Dasgupta, P., & Basu, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33125 · Cited by 155
Cell Therapy, a New Standard in Management of Chronic Critical Limb Ischemia and Foot Ulcer
Procházka, V., Gumulec, J., Jalůvka, F., Šalounová, D., Jonszta, T., Czerný, D., Krajča, J., Urbanec, R., Klement, P., Martinek, J., et al. (2010) · Cell Transplantation · doi:10.3727/096368910x514170 · Cited by 163
Carneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F. M., & Soares, R. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02240.x · Cited by 147
“Although the two drugs are derived from the same very specific murine monoclonal antibody against VEGF-A, they are different concerning molecular weight, affinity to VEGF and pharmacokinetic properties (Ferrara & Kerbel 2005; Ferrara et al. 2006; Bakri et al. 2007a,b).”
BackgroundCombination angiostatic therapy completely inhibits ocular and tumor angiogenesis
Dorrell, M. I., Aguilar, E., Scheppke, L., Barnett, F. H., & Friedlander, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607542104 · Cited by 147
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, T. O., & Omotuyi, O. I. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0035-0 · Cited by 175
Bidard, F., Mathiot, C., Degeorges, A., Étienne-Grimaldi, M.-C., Delva, R., Pivot, X. B., Veyret, C., Bergougnoux, L., de Crémoux, P., Milano, G. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq052 · Cited by 160
“The impairment of vascular endothelial growth factor-A actions (endothelial cell proliferation and migration, endothelial cell apoptosis inhibition, extracellular matrix remodelling, vasodilatation, increase of vascular permeability) [15] explains bevacizumab antitumoral effects together with its main side-effects.”
BackgroundTargeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 154
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schaefer, W., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2019) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 143
Dorrell, M. I., Aguilar, E., Jacobson, R., Trauger, S. A., Friedlander, J., Siuzdak, G. E., & Friedlander, M. (2009) · Glia · doi:10.1002/glia.20900 · Cited by 146
“…development of pathological neovascularization (NV) in the eye (Aiello et al. 1995; Caldwell et al. 2003; Ferrara and Kerbel 2005; Ng et al. 2006; Witmer et al. 2003), and anti-VEGF drugs are currently in clinical use to slow the progression of retinal vascular disease (Avery et al. 2006; Ng et…”
InfluentialThermodynamic and structural description of allosterically regulated VEGFR-2 dimerization
Brozzo, M. S., Bjelić, S., Kisko, K., Schleier, T., Leppänen, V., Alitalo, K. K., Winkler, F. K., & Ballmer‐Hofer, K. (2011) · Blood · doi:10.1182/blood-2011-11-390922 · Cited by 154
Taeger, J., Moser, C., Hellerbrand, C., Mycielska, M. E., Glockzin, G., Schlitt, H. J., Geissler, E. K., Stoeltzing, O., & Lang, S. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0312 · Cited by 148
“FGF signaling is not only involved in motility and survival of tumor cells, but also it is a crucial component of tumor angiogenesis (10, 12).”
BackgroundKluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder, W. J. M., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., & Nicolay, K. (2010) · Nano Letters · doi:10.1021/nl902659g · Cited by 146
The regulatory role of micro RNA s in angiogenesis‐related diseases
Sun, L., Li, W., Lei, F., & Li, X. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13700 · Cited by 161
“abnormal vasculature.(23) Thus, miRNAs may provide novel and useful”
BackgroundTargeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014665 · Cited by 143
“. Inhibition of angiogenesis has recently been introduced in the clinics as novel therapeutic option to block cancer progression”
BackgroundEssential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00002-8 · Cited by 141
“Tumor hypoxia is believed to represent an important inducer of tumor-associated VEGF (Dayan et al., 2008; Ferrara and Kerbel, 2005; Mantovani et al., 2002; Murdoch et al., 2008), which is an indispensable driver of tumor angiogenesis in preclinical mouse models (Ferrara and Kerbel, 2005; Kim et…”
BackgroundDisruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
Grabner, B., Schramek, D., Mueller, K. M., Moll, H. P., Svinka, J., Hoffmann, T., Bauer, E., Blaas, L., Hruschka, N., Zboray, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7285 · Cited by 145
Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D'Incalci, M., Cavalletti, E., Giavazzi, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2700 · Cited by 143
“This makes angiogenesis not only one of the hallmarks of cancers but also an important target for cancer therapy (3, 4).”
BackgroundLaxmikeshav, K., Pooja, K., & Shankaraiah, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21852 · Cited by 156
Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis
Oladipupo, S. S., Smith, C., Santeford, A., Park, C., Sene, A., Wiley, L. A., Osei-Owusu, P., Hsu, J., Zapata, N., Liu, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324235111 · Cited by 142
Zhou, W., Yao, N., Yao, G., Deng, C., Zhang, X., & Yang, P. (2008) · Chemical Communications · doi:10.1039/b808800d · Cited by 141
Lorenc, P., Sikorska, A., Molenda, S., Guzniczak, N., Dams‐Kozlowska, H., & Florczak, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117585 · Cited by 153
Dual targeting of epigenetic therapy in cancer
Hellebrekers, D. M. E. I., Griffioen, A. W., & van Engeland, M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.07.003 · Cited by 161
Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 156
Self-citationCan angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential
SLEVIN, M. A., Kumar, P., Gaffney, J. J., Kumar, S., & Krupiński, J. (2006) · Clinical Science · doi:10.1042/cs20060049 · Cited by 154
Treatment advances across the cervical cancer spectrum
Francoeur, A., Monk, B. J., & Tewari, K. S. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00977-w · Cited by 154
“This VEGF-induced angiogenesis has been correlated with more-invasive disease and a poorer prognosis in patients with cervical cancer 86–88 .”
Caveats of caveolin-1 in cancer progression
Burgermeister, E., Liscovitch, M., Röcken, C., Schmid, R. M., & Ebert, M. P. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.055 · Cited by 139
Huang, M., Zhang, D., Wu, J. Y., Xing, K., Yeo, E., Li, C., Zhang, L., Holland, E., Yao, L., Qin, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay7522 · Cited by 139
Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle
Birbrair, A., Zhang, T., Wang, Z., Messi, M. L., Mintz, A., & Delbono, O. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00245 · Cited by 152
“Its goal is to stimulate blood vessels to grow new blood vessels (Folkman, 1995; Isner, 1996; Ferrara and Kerbel, 2005).”
BackgroundVélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Quiroz-Mercado, H., & Mandava, N. (2013) · Retina · doi:10.1097/iae.0000000000000036 · Cited by 154
Properties of Protein Drug Target Classes
Bull, S. C., & Doig, A. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117955 · Cited by 135
“blood supply can be cut off by preventing angiogenesis, as done by the drug Bevacizumab’s inhibition of vascular endothelial growth factor A [16].”
BackgroundVoltage‐dependent anion channel 1 is involved in endostatin‐induced endothelial cell apoptosis
Yuan, S., Fu, Y., Wang, X., Shi, H., Huang, Y., Song, X., Li, L., Song, N., & Luo, Y. (2008) · The FASEB Journal · doi:10.1096/fj.08-107417 · Cited by 137
“The angiogenesis process can be regulated by a switch between concentrations of inducers and inhibitors in vivo (2), and many angiogenesis regulators have been developed as potential antitumor targets in clinical studies ( 3 ).”
BackgroundEvidente, A., Kireev, A. S., Jenkins, A. R., Romero, A. E., Steelant, W. F. A., slambrouck, S. V., & Kornienko, A. (2009) · Planta Medica · doi:10.1055/s-0029-1185340 · Cited by 143
“Some examples include the development of inhibitors of angiogenesis [22] and tumor cell invasion [23].”
de Paulis, A., Prevete, N., Fiorentino, I., Rossi, F. W., Staibano, S., Montuori, N., Ragno, P., Longobardi, A., Liccardo, B., Genovese, A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7322 · Cited by 140
“Pharmacological manipulation of the VEGF/VEGFR network, which is already showing promise in relation to neoplastic angiogenesis (65), might also be effective in disorders associated with basophil recruitment and activation.”
BackgroundPatterson, D. M., & Rustin, G. J. S. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.014 · Cited by 146
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.